| Target Price | $14.28 |
| Price | $1.48 |
| Potential |
864.87%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Phio Pharmaceuticals Corp. 2026 .
The average Phio Pharmaceuticals Corp. target price is $14.28.
This is
864.87%
register free of charge
$14.70
893.24%
register free of charge
$14.14
855.41%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Phio Pharmaceuticals Corp. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Phio Pharmaceuticals Corp. stock has an average upside potential 2026 of
864.87%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -9.05 | -1.84 |
| 81.07% | 79.67% | |
| P/E | negative |
3 Analysts have issued a Phio Pharmaceuticals Corp. forecast for earnings per share. The average Phio Pharmaceuticals Corp. EPS is
This results in the following potential growth metrics and future valuations:
Phio Pharmaceuticals Corp....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


